Background. Indonesia is the fourth highest country with tuberculosis burden in the world. Anti tuberculosis drugs such as isoniazid, rifampicin, and pyrazinamide can cause side effect called anti tuberculosis drug induced hepatitis (ATTDIH), but research about ATTDIH still few in Indonesia.
Objectives. This study aims to determine the profile of anti tuberculosis drug induced hepatitis patients at Atma Jaya Hospital in 2016.
Methods. This descriptive study is conducted retrospectively using medical record. The samples used were all tuberculosis patients at Atma Jaya Hospital in 2016 that met the inclusion criterias.
Results. Out of 609 tuberculosis patients, there were 2,13% of patients diagnosed with anti tuberculosis drug induced hepatitis. 84,6% had ALT more than 3 times the upper limit and 100% had AST more than 3 times the upper limit. Not all patients had a total bilirubin serum test, 15,4% had a normal total bilirubin serum, and 15,4% had total bilirubin serum increase of more than 1,5 md/dl.
Conclusions. The prevalence of anti tuberculosis drug induced hepatitis in Atma Jaya Hospital in 2016 was 2,13%, according to incidience data in China in 2016 (2.55%). Reintroduction method varies greatly as it depends on clinical manifestations and patient constancy for control. The outcome of therapy can not be known entirely because the data retrieval period is limited. Abdominal ultrasound data was found only in 38,5% patients. |